New Clinical Muedzo weMetastatic Castration-Resistant Prostate Cancer

January 20, 2022
by mupepeti
Add Comment
3 min kuverenga
en English
af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sudanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu
rakanyorwa mupepeti

ESSA Pharma Inc., kambani yemishonga yekiriniki yakatarisana nekugadzira nzira itsva dzekurapa kenza yeprostate, nhasi yazivisa murwere wekutanga akaiswa muongororo inotsigirwa neKambani yeChikamu 1/2 kuti iongorore kuchengetedzeka, kushivirira uye kushanda kwekutanga kweESSA's. mutungamiri wechigadzirwa, EPI-7386, yekutanga-mu-kirasi N-terminal domain androgen receptor inhibitor, pamwe chete neAstellas Pharma Inc.'s uye Pfizer Inc.'s ligand-binding domain androgen receptor inhibitor, enzalutamide, mune varwere vane chirwere. metastatic castration-inodzivirira kenza yeprostate.

Print Friendly, PDF & Email

"Kutangwa kweiyi muedzo wekusanganiswa neAstellas inguva yemvura yeESSA sezvatinoongorora zvingave kliniki inobatsira yekudzivisa androgen receptor kuburikidza nenzira mbiri dzakasununguka mukurapa kwevarwere vane mCRPC vasati vagamuchira kurapwa nechizvarwa chechipiri antiandrogen. mushonga,” akadaro Dr. David. R. Parkinson, Chief Executive Officer, ESSA Pharma Inc. "Kubatanidza marapirwo edu maviri achatarisa panguva imwe chete kumativi ose e-androgen receptor. Mune preclinical modhi, takaona kuti kusanganisa EPI-7386 neazvino antiandrogens kunogona kutungamirira mukudzika uye kwakakura inhibition ye androgen biology. Iyi Phase 1/2 muyedzo inoratidza yekutanga yeakatevedzana yezvidzidzo zvekiriniki kuongorora EPI-7386 pamwe chete neazvino antiandrogen marapirwo muvarwere vane mCRPC, pamwe nekuwedzera Phase 1/2 musanganiswa miedzo inotarisirwa kutanga muna 2022.

Iyo Phase 1/2 kiriniki yekuyedza (NCT05075577) inotanga nechikamu chekutanga chikamu umo madosi emushonga wega wega anogadziriswa achiteverwa nechikamu chechipiri umo mumiriri mumwechete enzalutamide inofananidzwa nemusanganiswa we enzalutamide uye EPI-1. Chidzidzo chechikamu che2 chinotarisirwa kunyoresa kusvika kuvarwere ve7386 mCRPC vasati varapwa nechizvarwa chechipiri antiandrogen therapies. Chinangwa chechikamu chechikamu chechidzidzo ndechekuongorora kuchengetedzeka uye kushivirira kwemusanganiswa wemushonga uye kumisikidza yakakurudzirwa chikamu 1 madosi eEPI-30 uye enzalutamide kana ichiiswa musanganiswa. Chikamu chechipiri chekudzidza chinotarisirwa kunyoresa varwere ve1 mCRPC vasati varapwa nechizvarwa chechipiri antiandrogen therapies. Chinangwa chechikamu chechipiri chikamu chechidzidzo ndechekuongorora kuchengetedzeka, kushivirira uye antitumor chiitiko cheEPI-2 pamwe chete neyakagadzika dosi re enzalutamide zvichienzaniswa ne enzalutamide semumiririri mumwechete.

Print Friendly, PDF & Email

Ungazvidyawo kufanana

Nezvomunyori

mupepeti

Mupepeti mukuru we eTurboNew ndiLinda Hohnholz. Iye anogara muTN HQ muHonolulu, Hawaii.

Tarisa zvese zvawatumira

Leave a Comment